- I think the biggest breakthroughs are yet to come: early reports confirm it's extremely effective in treating addictions, including alcohol addiction. I believe this will be seen on par with insulin or even penicillin in couple decades from now.
by Uncle_Clark
0 subcomment
- This will be huge. Companies like Hims and Ro charge thousands of dollars a month with drugs that don't have the patents expire. I'm hopeful this will expand the ability to receive treatment and also allow trials to be tested at greater length to understand long-term effects.
by thewhitetulip
2 subcomments
- It just did. The patent expired on March 20 in India.
There are 10+ firms vying ro bring a generic glp1 anywhere the patent has expired. How effective these generics will be is yet to be seen.
This might cause a lot of problems because some people are taking glp1 for "my wedding is in 1 month and I gotta reduce 10kg by then"
by therealpygon
1 subcomments
- > That delay is due to special regulatory protections that are intended to encourage innovation by extending a brand-name drugmaker’s monopoly.
Pure profit protection when they make back enough money to fund every one of their drugs off a single patent that they continue to renew for 20 years by slightly modifying the syringe to now have an amazing new innovation like an integrated safety cap, or some other drug-irrelevant bs.
Both Copyright and Patents in the US need 21st century reform to something that is reasonable for the speed of modern technology.
by androiddrew
0 subcomment
- Good, because it’s fucking ridiculous that pharma gets special patent loop holes to maintain a monopoly beyond what the basic protection grants.
by 7777777phil
0 subcomment
- Novo already guided for its first revenue decline in modern history (adjusted sales down 5-13% for 2026). Stock is down 75% from June 2024 peak. The problem isn't just generics, Lilly's tirzepatide beat CagriSema in the head-to-head, and Lilly has orforglipron (oral, way cheaper to manufacture) coming. At 11x forward earnings Novo is pricing in catastrophe, buuuuut.. the structural problems are real this time.
by ChrisArchitect
0 subcomment
- Related:
Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists
https://news.ycombinator.com/item?id=47461018
- [dead]
- whats the tell?
by up2isomorphism
0 subcomment
- Go Generic? It sucks.
- Anyone else clicked on this expecting an article about Go Generics?
- When I first saw ads of "lost weight magic drug in a syringe" in NY Subway I thought it was some intelligent, sarcastic and learning campaign.
Then I realized US is selling strong, sometimes dangerous diabetes drug as "eat more, weigh less" spell. I’m more than I amazed! Freedom is awesome.
Hacker News